Halma, a safety, health and environmental technology group, agreed to acquire NovaBone Products, a designer and manufacturer of US FDA-approved synthetic bone graft products, for $122m, including a $25m earn-out consideration. "NovaBone extends our Medical sector's presence in surgical applications, adding a new niche within the orthopedics market, which is growing fast due to the ageing population and increasingly sedentary lifestyles causing joint problems. It has strong technology and knowhow within the fast-growing biologics segment, developing biomaterials that harnesses the body's natural healing process to accelerate bone growth," Andrew Williams, Halma Group Chief Executive.